53917-47-8

Basic information

• Product Name: N^α-formyl-N^Ε-CBZ-L-lysine
• Synonyms: N^α-formyl-N^Ε-CBZ-L-lysine
• CAS NO: 53917-47-8
• Molecular Weight: 308.334
• Mol File: 53917-47-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N^α-formyl-N^Ε-CBZ-L-lysine(CAS DataBase Reference)
• NIST Chemistry Reference: N^α-formyl-N^Ε-CBZ-L-lysine(53917-47-8)
• EPA Substance Registry System: N^α-formyl-N^Ε-CBZ-L-lysine(53917-47-8)

Safety Data

• Hazardous Substances Data: 53917-47-8(Hazardous Substances Data)

Upstream product

• 1426213-63-9 N(ε)-benzoyloxycarbonyl-L-lysine-tert-butyl ester hydrochloride 
• 64-18-6 formic acid 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 
• 50-00-0 formaldehyd 

Downstream Products

• 107086-18-0 - 
• 106525-37-5 - 
• 106279-16-7 - 
• 106279-38-3 - 
• 887610-09-5 - 
• 107895-16-9 - 
• 105185-67-9 - 
• 92514-89-1 (S)-6-Benzyloxycarbonylamino-2-((S)-6-benzyloxycarbonylamino-2-{2-[(S)-6-benzyloxycarbonylamino-2-((S)-6-benzyloxycarbonylamino-2-formylamino-hexanoylamino)-hexanoylamino]-acetylamino}-hexanoylamino)-hexanoic acid methyl ester 
• 92514-85-7 (S)-6-Benzyloxycarbonylamino-2-((S)-6-benzyloxycarbonylamino-2-{2-[2-(2-formylamino-acetylamino)-acetylamino]-acetylamino}-hexanoylamino)-hexanoic acid methyl ester 
• 92514-84-6 (S)-6-Benzyloxycarbonylamino-2-{(S)-6-benzyloxycarbonylamino-2-[2-(2-formylamino-acetylamino)-acetylamino]-hexanoylamino}-hexanoic acid methyl ester 
• 92514-83-5 (S)-6-Benzyloxycarbonylamino-2-[(S)-6-benzyloxycarbonylamino-2-(2-formylamino-acetylamino)-hexanoylamino]-hexanoic acid methyl ester 
• 92514-93-7 [(S)-5-Azidocarbonyl-5-((S)-6-benzyloxycarbonylamino-2-formylamino-hexanoylamino)-pentyl]-carbamic acid benzyl ester 
• 92514-92-6 N^α-formyl-N^ε-Z-L-lysyl-L-lysine hydrazide 
• 92514-91-5 C₆₄H₈₅N₁₁O₁₇ 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS

Compositions and methods for the treatment of fungal infections including compounds containing a pathogen pattern recognition receptor ligand and a β 1,3-glucan synthase inhibitor are disclosed. In particular, compounds containing a lipopeptide moiety and

Polypeptides. XIV. The synthesis of some oligopeptides containing lysine and glutamic acid residues.

-